1STBIO develops novel therapeutics targeting neurodegenerative diseases, immuno-oncology, and rare diseases through a genomic-based target discovery platform. The company addresses significant unmet medical needs by transforming breakthrough scientific discoveries into effective medicines for patients.

D'CENT offers a biometric hardware wallet that utilizes fingerprint authentication to securely store and manage over 3,600 cryptocurrencies and NFTs offline. This solution addresses the risk of online attacks by ensuring private keys are generated and stored within the device, providing users with enhanced security and control over their digital assets.

Dewcell Biotherapeutics develops synthetic platelets using biomimetic technology and stem cell-derived processes to create transfusable blood products. The company addresses the critical shortage of donor platelets by establishing a consistent and high-quality production system for these essential components of blood.

Eutilex develops immunotherapy technologies, including anti-tumor T cell therapy and antibody therapeutics, to treat incurable diseases. Their focus on T cell and CAR-T therapies aims to provide effective treatment options for patients with resistant and untreatable conditions.

This startup develops three-dimensional printing materials, including filaments, resins, and powders, specifically for dental applications such as clear aligners and permanent tooth restorations. Their technology addresses the limitations in the global orthodontic market by providing high-quality, UV-curable materials that enhance dental health outcomes.

The startup develops human microbiota utilizing differentiated separation technology for anaerobic intestinal microbe strains, targeting the prevention of diverse diseases and enhancing cancer immunotherapy. Their approach enables physicians to perform multi-omics analysis, facilitating clinical research and drug discovery in metabolic and brain diseases.

This startup develops micro-LED display core components and technologies, including damage-free micro LED separation and micro LED bonding, to facilitate efficient display manufacturing. Their solutions streamline the production process, reducing complexity and enhancing yield in micro-LED display fabrication.

The startup offers a blockchain-based digital platform for trading real estate securities, enabling retail investors to access small and medium-sized commercial real estate investments. By facilitating the indirect investment process, the platform simplifies the trading of digital real estate securities, enhancing liquidity and accessibility for individual investors.

The startup develops treatments for metabolic diseases by utilizing technology to reduce advanced glycation endproducts (AGEs), which are harmful sugar toxins. This approach enables the creation of customized medical foods tailored to individual patient needs through consultations at hospitals, clinics, and pharmacies.

The startup develops therapeutic drugs that leverage the ubiquitin-proteasome system to regulate protein levels in the body. This approach targets diseases such as cancer by utilizing natural biological processes for protein degradation.

The startup develops a cancer diagnosis technology that detects drug resistance signals by monitoring the activation of cancer signal pathways through direct observation of relevant proteins. This enables healthcare providers to predict drug efficacy in real-time, improving treatment decisions for patients.

SoVarGen is a biotechnology company developing targeted pharmacological treatments for patients with neurological diseases, utilizing advanced drug delivery systems to enhance therapeutic efficacy. The company focuses on addressing the unmet medical needs of individuals suffering from conditions such as Alzheimer's and Parkinson's disease, aiming to improve patient outcomes and quality of life.